European Patients Forum, logo.

EUCAPA

Project information

  • Full title: European Capacity Building for Patients (EUCAPA)
  • Duration: 24 months (1 March 2023 – 28 February 2025)
  • Status: ongoing, coordinated by EURORDIS
  • Funding programme: the project is a EU4Health Programme co-funded by the European Union, under call EU4H-2022-PJ.

What will the project do?

EUCAPA will ensure that patients and patient organisations have the necessary knowledge of the HTA process to be meaningfully involved in HTA (both scientific consultations and assessments), as foreseen by the new Regulation on HTA (EU) 2021/2282 that will start assessing health technologies in January 2025. After undergoing the training programmes, patient experts will acquire the necessary skills, knowledge, and understanding of HTA, that will allow them to constructively participate and present their lived experience in assessing health technologies.

What are the expected outcomes?

  • Building the skills and knowledge of patient advocates who will participate in HTAs
  • Preparing patient organisations to respond to the requests for patient experts from European HTA Cooperation.
  • Ensuring that the HTA Cooperation includes the patient perspective from the start, foreseen in 2025.
  • Ensuring that patients and patient organisations have the necessary knowledge of the HTA process and its legal framework as well as the skills and knowledge of HTA methods needed to participate and advocate.
  • Raising awareness among the wider public about the HTA Regulation and benefit HTA bodies

What is EPFs role?

EPF will activate the patient community and will hold a central role in communicating and disseminating project results to a wider audience to promote awareness and uptake.

Consortium

The EUCAPA consortium is made up of two patient organisations (EURORDIS – project coordinator and EPF) and a university – UMIT Tirol.

EURORDIS  - Rare Diseases Europe (European Organisation for Rare Diseases), France, is the coordinator of this project. EURORDIS is a unique, non-profit alliance of 1000 rare disease patient organisations from 74 countries that work together to improve the lives of the 30 million people living with a rare disease in Europe.

UMIT TIROL is specialised in delivering training courses in public health and health sciences, and is widely recognised for developing dedicated and pedagogically innovative modules covering different level of expertise on HTA.